Skip to main content

Advertisement

Table 3 Subgroup analysis of SVR12 for GT1

From: Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Response GT1 (N = 1076) Heterogeneity Pb-value Studies
  Total, n/N Rate (95%CI) I2(%) P a   
Overall 1025/1076 96.2 (94.8–97.4) 38 0.13   10
By the different duration of treatment 0.9668  
 12 weeks 364/384 96.2 (92.5–98.9) 38 0.15   6
 24 weeks 52/55 96.6 (82.5–100.0) 65 0.09   2
By regimens 0.8742  
 OBV/PTV/r + DSV 163/170 97.0 (93.3–99.5) 0 0.41   4
 OBV/PTV/r + DSV + RBV 350/368 95.8 (91.6–98.8) 56 0.06   5
By genotypes 0.6031  
 1a 583/608 96.2 (94.5–97.7) 49 0.10   5
 1b 311/326 95.9 (93.3–98.0) 14 0.33   5
By treatment history 0.6859  
 TN patients 407/423 96.9 (94.9–98.5) 41 0.15   5
 TE patients 262/274 98.7 (96.1–100.0) 46 0.12   5
By the presence or absence of cirrhosis 0.2581  
 Cirrhosis 207/219 97.6 (94.2–99.7) 45 0.11   6
 Non-cirrhosis 753/781 96.9 (95.5–98.2) 20 0.28   6
By baseline HCV RNA 0.3939  
 <6 log10 IU/m L 293/304 97.0 (87.8–100.0) 89 <0.01   3
 ≥6 log10 IU/m L 160/171 94.0 (89.6–97.4) 0 0.87   3
By CD4 cell counts/mm3 0.7810  
 ≤500 129/132 97.8 (94.2–99.8) 0 0.71   2
 >500 246/254 96.9 (94.3–98.8) 0 0.38   2
Platelet counts/μL 0.7925  
 ≤100,000 37/38 98.2 (89.8–100.0) 0 0.41   2
 >100,000 338/348 97.2 (95.1–98.7) 0 0.38   2
By IL 28B genotypec 0.9685  
 CC 37/38 97.4 (89.0–100.0)   1
 Non-CC 101/105 97.9 (93.3–100.0) 71 0.06   2
  1. *OBV ombitasvir, PTV paritaprevir, r ritonavir, DSV dasabuvir, RBV ribavirin, GT genotype, TN treatment-naive, TE treatment-experienced, CI confidence interval
  2. aTest of heterogeneity
  3. bTest for subgroup differences
  4. cOnly one article had the SVR rate of IL 28B CC genotype, thus, there were no test of heterogeneity for it